BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 32974862)

  • 1. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
    Song P; Song B; Liu J; Wang X; Nan X; Wang J
    Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
    Chen L; Bi S; Hou J; Zhao Z; Wang C; Xie S
    Cell Commun Signal; 2019 Apr; 17(1):31. PubMed ID: 30971268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
    Huynh N; Liu KH; Baldwin GS; He H
    Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of PAK1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through the ERK Pathway.
    Wang S; Wang SY; Du F; Han Q; Wang EH; Luo EJ; Liu Y
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):602-610. PubMed ID: 31394555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.
    Chang L; Fang S; Chen Y; Yang Z; Yuan Y; Zhang J; Ye L; Gu W
    Lipids Health Dis; 2019 May; 18(1):118. PubMed ID: 31122252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
    Liu X; Sun L; Zhang S; Zhang S; Li W
    J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.
    Zhang B; Tao F; Zhang H
    Mol Med Rep; 2018 Apr; 17(4):4899-4908. PubMed ID: 29393472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
    Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway.
    Ren M; Xu W; Xu T
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1014-1021. PubMed ID: 30880481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.
    Wei CH; Wu G; Cai Q; Gao XC; Tong F; Zhou R; Zhang RG; Dong JH; Hu Y; Dong XR
    J Hematol Oncol; 2017 Jun; 10(1):125. PubMed ID: 28629431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M; Zhou LY; Xu N; An Q
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRPX2 promotes cell proliferation and invasion via activating FAK/SRC/ERK pathway in non-small cell lung cancer.
    Li X; Liu J; Sun H; Zou Y; Chen J; Chen Y; Chen C; Wu X
    Acta Biochim Pol; 2020 Jun; 67(2):165-172. PubMed ID: 32550700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
    Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
    Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
    BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.